We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01732276
Recruitment Status : Unknown
Verified November 2012 by yu gengsheng, Jiangmen Central Hospital.
Recruitment status was:  Not yet recruiting
First Posted : November 22, 2012
Last Update Posted : December 3, 2012
Information provided by (Responsible Party):
yu gengsheng, Jiangmen Central Hospital

Brief Summary:

Breast cancer is a heterogeneous disease and can be classified into several distinctive subgroups. Triple-negative breast cancer(TNBC) is defined by lack of estrogen(ER), progesterone(PR) immunoreactivity and lack of human epidermal receptor-2(HER2) overexpression. TNBC comprises around 15% of all breast cancer and is characterized by its aggressive clinical behavior and insensitivity toward available targeted treatment strategies such as endocrine and anti-HER2 therapies.Although TNBC is sensitive to chemotherapy,early relapse with metastatic disease is common and the prognosis is poor. Development Of novel treatment strategies is,therefore,needed and the study of other potential targets in TNBC,like tyrosine kinase receptors,is a topic of interest.

Epidermal Growth Factor Receptor(EGFR) is a transmembrane receptor tyrosine kinase that encoded by cell erythroblastosis virus oncogene B1(C-erbB1) and belongs to the HER/Erythroblastosis virus oncogene B(ErbB) family. By several signal pathways,EGFR regulates cell proliferation, differentiation, apoptosis, invasion,and angiogenesis,and serves as a poor prognostic factor.EGFR is overexpressed in a variety of malignancies including TNBC.Gene expression profiling and immunohistochemical studies have indicated that 40 to 60% of TNBCs exhibit EGFR expression and gene amplification was found in 18% of this subgroup,but EGFR mutation was rare in TNBC.

By far,the role of gefitinib, an EGFR tyrosine kinase inhibitor(TKI),in the metastatic TNBC has not been identified. Most clinical trials about EGFR TKIs in the breast cancer have one or more limitations including:1) the study population had received heavily pretreatment; 2)the enrolled patients included several subgroups of breast cancer; 3)the expression of EGFR was not clear in the enrolled patients.

Here, the investigators launch a prospective clinical trial, and about 50 patients with triple-negative,EGFR positive metastatic breast cancer that have received at least second line therapy will be enrolled. these patients will be treated with gefitinib, the toxicity and effects of gefitinib will be recorded prospectively to evaluate the role of gefitinib in the metastatic TNBC.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: gefitinib Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Study Start Date : January 2013
Estimated Primary Completion Date : April 2015
Estimated Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Gefitinib
U.S. FDA Resources

Arm Intervention/treatment
Experimental: gefitinib
gefitinib tablet 250mg/day by mouth until disease progression
Drug: gefitinib
Other Name: IRRESA

Primary Outcome Measures :
  1. clinical benefit rate [ Time Frame: one month ]
    The primary end point is objective clinical benefit rate defined as objective response or stable disease for≥24wk

Secondary Outcome Measures :
  1. progress-free survival(PFS) [ Time Frame: every 4 weeks ]
    Progress-free survival(PFS)is defined as the time from start of treatment to progression or death.

Other Outcome Measures:
  1. Toxicity [ Time Frame: twice weekly ]
    Toxicity is assessed twice weekly and adverse effects(AEs) are classified according to the National Cancer Institute Common Toxicity Criteria(NCI-CTC).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥18 years of age
  • ≥1 measurable or assessable lesion
  • Eastern Cooperative Oncology Group(ECOG)performance status of 0-2
  • adequate renal,hepatic and hematological function
  • a life expectancy of >12 weeks
  • histologically proven EGFR positive metastatic TNBC

Exclusion Criteria:

  • brain metastasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01732276

Contact: gengsheng yu 0086-0750-3165915 gengsheng_yu@hotmail.com

Sponsors and Collaborators
Jiangmen Central Hospital
Principal Investigator: gengsheng yu Department of oncology, Jiangmen central hospital, Jiangmen, China

Responsible Party: yu gengsheng, vice director of oncology department, Jiangmen Central Hospital, Jiangmen Central Hospital
ClinicalTrials.gov Identifier: NCT01732276     History of Changes
Other Study ID Numbers: 20120314
First Posted: November 22, 2012    Key Record Dates
Last Update Posted: December 3, 2012
Last Verified: November 2012

Keywords provided by yu gengsheng, Jiangmen Central Hospital:
Triple-negative breast cancer
Epidermal growth factor receptor

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action